Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812, Japan.
J Control Release. 2010 Oct 15;147(2):261-8. doi: 10.1016/j.jconrel.2010.07.100. Epub 2010 Jul 18.
Ligand-based targeted delivery is an emerging platform in nanomedicine. We report herein on a peptide modified nanocarrier for a ligand-based targeted delivery system. The liposomal surface of the carrier was first modified with a linear peptide, followed by an adipose tissue-specific circular peptide (KGGRAKD) via a polyethylene glycol (PEG) spacer. To evaluate the specificity of the carrier, we purified primary cells from the endothelium of adipose tissue. The liposomes bound only to isolated primary cultured endothelial cells derived from inguinal adipose tissue (pcEC-IWAT) and not to other endothelial cell lines, such as MBEC-4 and MFLM-4. Cellular uptake was confirmed both qualitatively and quantitatively by confocal laser scanning microscopy (CLSM) and flow cytometry. The mechanism for the intracellular uptake of tPep-PEG-LPs into pcEC-IWAT, as evidenced by three independent experiments, involves saturation of receptor binding sites by excess free peptide, the blocking of receptors by an anti-prohibitin antibody and low temperature (4°C) experiments, resulting in the inhibition of uptake of tPep-PEG-LPs into pcEC-IWAT, suggesting that receptor mediated endocytosis largely contributed to the observed cellular uptake. A co-localization study using double labeled modified liposomes (lipid membrane: NBD-DOPE and aqueous phase: rhodamine) indicated that a predominant part of tPep-PEG-LPs was found without co-localization with lysosomes and retained their intactness. The selective delivery of tPep-PEG-LPs to endothelial cells in adipose tissue represents a potential approach for the design of diverse nanocarrier-based targeted delivery systems for targeting the vasculature in adipose tissue.
基于配体的靶向递药是纳米医学中的一个新兴平台。本文报道了一种肽修饰的纳米载体,用于基于配体的靶向递药系统。载体的脂质体表面首先通过聚乙二醇(PEG)间隔物用线性肽修饰,然后用脂肪组织特异性环肽(KGGRAKD)修饰。为了评估载体的特异性,我们从脂肪组织的内皮中纯化了原代细胞。脂质体仅与从腹股沟脂肪组织(pcEC-IWAT)分离的原代培养的内皮细胞结合,而不与其他内皮细胞系如 MBEC-4 和 MFLM-4 结合。通过共聚焦激光扫描显微镜(CLSM)和流式细胞术定性和定量证实了细胞摄取。通过三项独立的实验证实,tPep-PEG-LPs 进入 pcEC-IWAT 的细胞内摄取机制涉及过量游离肽对受体结合位点的饱和、抗抑素抗体对受体的阻断以及低温(4°C)实验,导致 tPep-PEG-LPs 进入 pcEC-IWAT 的摄取被抑制,表明受体介导的内吞作用在很大程度上促成了观察到的细胞摄取。使用双重标记修饰的脂质体(脂质膜:NBD-DOPE 和水相:罗丹明)进行的共定位研究表明,tPep-PEG-LPs 的主要部分没有与溶酶体共定位,并保持其完整性。tPep-PEG-LPs 向脂肪组织内皮细胞的选择性递药为设计用于靶向脂肪组织血管的各种基于纳米载体的靶向递药系统提供了一种潜在的方法。